about
Bromperidol decanoate (depot) for schizophreniaBromperidol decanoate (depot) for schizophreniaOlanzapine depot for schizophreniaFosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration.Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.Depot perphenazine decanoate and enanthate for schizophrenia.Antipsychotic dosing: how much but also how often?Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999.Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatmentPharmacological treatment strategies for schizophrenia.Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective.Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.Role of in vitro release models in formulation development and quality control of parenteral depots.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.A review of olanzapine pamoate.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.A review of paliperidone palmitate.Drug safety evaluation of olanzapine pamoate.Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaThree-month paliperidone palmitate - a new treatment option for schizophrenia.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics.Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine.Long-acting risperidone in the treatment of schizophrenia: an evidence-based approach.Calcium-dependent signaling in Dupuytren's disease.Development of Risperidone PLGA Microspheres.Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
P2860
Q24202780-6A5269E4-FD56-472D-9138-2AC5E9BA3631Q24234287-40C092F5-DA86-4A16-9FAA-3A9CB94D5A9DQ24240925-7F8B2511-4637-4EAE-9D93-C514D701C7D6Q31949056-66466687-2E64-4A0B-A426-8FAFF04BD0F6Q33908318-B742C63C-F1D3-4D20-AC52-CA4C49F20C2AQ33908329-6213D55A-0221-4912-9907-706394E67197Q34023214-8D9BD664-AEB9-4A50-8D3D-3AACE3669DAFQ34386881-A155014B-2802-4C68-A12E-A1A47A01C1B4Q34418847-62DCEAD1-693E-4C2C-83B0-21FBA6D2E956Q34560335-C870DED0-91C4-436A-A0DB-6A7FF0107CB2Q35804079-DCBEEA64-DEEB-4312-8670-732B63D8E02CQ35968139-D275E5A2-F5EE-48DF-80B5-7FA1FE8D9573Q36107179-9FBB0CDE-0DC6-431A-A406-1CAE6076BC91Q36129913-4997B6B0-063C-499E-95F9-66CC70F6DF56Q36168916-6CA7262E-2128-4FE1-A6AD-487E816ACC27Q37418931-FD6D0A34-8BBB-4DDF-9F05-A27A8EA5A190Q37639309-2793F61B-DA8D-4865-B619-D8692195E14AQ37760926-AC92A5F0-2687-449C-A2E2-4CC33467BAFBQ38022638-ACC5EF4B-5E7B-44B8-AD80-F8F3455AFF78Q38042430-82FD3726-37E2-4E50-87EA-046CA5350C82Q38064842-62B22938-910C-4DA1-9AB5-07A5C77E66B2Q38067137-0627958B-684D-43A9-A682-C64D8E5F3A4DQ38136262-946057B7-3DDF-47D8-BF29-34946863093DQ38156171-2C46B06B-482A-4835-B9F1-73DE6D722DAAQ38271353-83BC5062-186C-4618-9253-AA23CFC7AD3DQ38364268-702A9BED-8F47-4283-97FB-D4F8AE094122Q38840088-77098253-B223-473B-B90A-B7F3D5774CE4Q38851847-CC22077E-46EE-4655-83D9-81213359131FQ38852539-47B7AB4F-E18D-4CA0-AC0C-4CBD4BD756DEQ40427430-E75165BE-20A7-4381-B405-17451F4177E4Q40530811-B05AB9F6-FF2D-4075-9EF5-0930E0C36FE0Q41248610-55614CB0-C11F-4FA1-9E95-13D7CFAA6A03Q41826371-1D45724C-3007-432A-910A-C83B6BDCD86DQ41962765-98A2571B-5B67-4877-AB47-1EC186C030CAQ42427644-2A7BEA5F-6907-44B0-B363-ECFD780C8516Q42520005-C59E406A-D0B2-4E49-8862-0AE1A1D2748EQ42659773-306DE589-EE52-4B8D-9132-447867CB7A10Q42687642-6B054122-C682-4DCC-BF90-A94C13EA07CFQ43952283-04E29CD8-5C63-49C8-9EFC-94C30390238CQ44228933-B27E87DA-FFF7-4A15-98B4-765443BE6B5B
P2860
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Depot antipsychotic drugs. Place in therapy.
@ast
Depot antipsychotic drugs. Place in therapy.
@en
Depot antipsychotic drugs. Place in therapy.
@nl
type
label
Depot antipsychotic drugs. Place in therapy.
@ast
Depot antipsychotic drugs. Place in therapy.
@en
Depot antipsychotic drugs. Place in therapy.
@nl
prefLabel
Depot antipsychotic drugs. Place in therapy.
@ast
Depot antipsychotic drugs. Place in therapy.
@en
Depot antipsychotic drugs. Place in therapy.
@nl
P2093
P1433
P1476
Depot antipsychotic drugs. Place in therapy.
@en
P2093
Metalon L [corrected to Matalon L
Watanabe MD
P304
P356
10.2165/00003495-199447050-00004
P577
1994-05-01T00:00:00Z
P6179
1041514048